Natera
 | This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (March 2019) |
| File:Natera logo.gif | |
| Company type | Public |
|---|---|
| Nasdaq: NTRA Russell 2000 Component | |
| Industry | Genetic testing |
| Founded | 1 January 2004  |
| Headquarters | San Carlos, California |
Key people | Steve Chapman (CEO) Jonathan Sheena (CTO) Matthew Rabinowitz (Executive Chairman) |
| Revenue |  US$ 210.9 million (2017) |
| Website | www.natera.com |
Natera (previously Gene Security Network) is a genetic testing company that operates a CLIA-certified laboratory in San Carlos, California.[1] The company specializes in analyzing microscopic quantities of DNA for reproductive health indications to provide preconception and prenatal genetic testing services to OBGYN physicians and in vitro fertilization centers.[2]
In early 2013, the company launched Panorama, a non-invasive prenatal test for pregnant women that screens for the most common chromosomal anomalies in a fetus as early as nine weeks of gestation.[3] Other services include tests for preimplantation genetic diagnosis (PGD) and miscarriage testing to determine the cause of the loss of the pregnancy.[4] A non-invasive paternity test based on Natera’s technology, was brought to market in August 2011 through a partnership with DNA Diagnostics Center (DDC), which holds a license to the technology in the United States.[5]
In July 2015, Natera conducted an initial public offering of common stock at a price of $18.00 per share. The shares trade on the Nasdaq Global Select Market under the symbol "NTRA."[6]
Panorama Test
Natera launched a non-invasive prenatal test (NIPT) in February 2013 called Panorama, that uses an advanced bioinformatics-based algorithm to analyze the cell-free fetal DNA that is found in the mother’s blood. Panorama detects chromosome abnormalities, including Trisomy 21, the cause of Down syndrome, Trisomy 18, the cause of Edwards syndrome, Trisomy 13, the cause of Patau syndrome, sex chromosome abnormalities, triploidy and certain microdeletions as early as the first trimester of pregnancy. Using its patented SNP Technology, it is the only commercially available NIPT that differentiates maternal and fetal (placenta) DNA which in turn allows it to be the only commercially available NIPT that can detect Vanishing Twin and Triploidy and in twin pregnancies, individual gender and tell whether it’s a identical or fraternal twin pregnancy.[7][8][9] A clinical study evaluating Natera’s NIPT is funded by the National Institutes of Health, and is currently ongoing.
Competition
Companies also offering non-invasive prenatal genetic testing include Sequenom, Ariosa (Harmony Prenatal Test), Yourgene Health (the IONA test), Ravgen, and Verinata Health. Other companies and universities that are working towards developing non-invasive prenatal testing include Stanford University,[10] Fluidigm, and Ikonisys.
References
- ^ Leuty, Ron (6 January 2012). "Prenatal testing company raises $20M". San Francisco Business Times. Retrieved 2020-11-12.
{{cite web}}: CS1 maint: url-status (link) - ^ Leuty, Ron (4 September 2012). "One-on-One with Natera founder Jonathan Sheena". San Francisco Business Times. Retrieved 2020-11-12.
{{cite web}}: CS1 maint: url-status (link) - ^ "Natera Launches Noninvasive Prenatal Test; Quest to Offer in Limited Areas by March, Nationwide in April" – via www.genomeweb.com.
- ^ "Miscarriage Mysteries Create New Market for Natera - Xconomy". 12 February 2014.
- ^ "GSN Races to Improve Prenatal Tests for Genetic Conditions" – via www.bloomberg.com.
- ^ "Natera, Inc. Common Stock (NTRA) Real-Time Stock Quote - NASDAQ.com". www.nasdaq.com. Retrieved 2018-06-28.
- ^ "Innovator: Matt Rabinowitz Sifts Gene Data for Healthy Pregnancies". 26 April 2013 – via www.bloomberg.com.
- ^ Nicolaides KH, Syngelaki A, Gil MM, Quezada MS, Zinevich Y (October 2013). "Prenatal Detection of Fetal Triploidy from Cell-Free DNA Testing in Maternal Blood". Fetal Diagnosis and Therapy. 35 (3): 212–7. doi:10.1159/000355655. PMID 24135152.
- ^ Check Hayden, Erika (6 March 2014). "Prenatal-screening companies expand scope of DNA tests". Nature. 507 (7490): 19–19. doi:10.1038/507019a.
- ^ "Non-invasive prenatal test for Down's syndrome developed". BioNews.